← All trials
NCT01513759
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2012
- Primary completion
- Feb 1, 2013
- Completion date
- Apr 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Ekos CorpLead sponsor
- Advent HealthOverall official - principal investigator
- Medical Center of Central GeorgiaOverall official - principal investigator
- University of KentuckyOverall official - principal investigator
- Yeshiva UniversityOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- Brown UniversityOverall official - principal investigator
- Columbia UniversityOverall official - principal investigator
- Baptist HealthOverall official - principal investigator
- Memorial Medical Center - ModestoOverall official - principal investigator
- Christiana HospitalOverall official - principal investigator
- Holmes Regional Medical CenterOverall official - principal investigator
- Lakeland Regional Medical CenterOverall official - principal investigator
- Orlando Regional Medical CenterOverall official - principal investigator
- East Jefferson General HospitalOverall official - principal investigator
- Overlook Medical CenterOverall official - principal investigator
- Providence Memorial Hospital - Sierra Vista HospitalOverall official - principal investigator
- Mt. Carmel EastOverall official - principal investigator
- Holy Name Medical Center, Teaneck, NJOverall official - principal investigator
- Inova Health SystemOverall official - principal investigator
- Harvard UniversityStudy chair
- University of ConnecticutOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.